ArticleScientific reports2025
Multi-omics reveals the mechanism of vagus nerve stimulation in the treatment of chronic congestive heart failure.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The vagus nerve as a neurovisceral interface: a comprehensive review.Frontiers in neuroscience · 2026Review
- Establishment and validation of an interpretable machine learning-based predictive model for risk of post-PCI in-hospital heart failure in AIHD patients.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
The potential benefits and underlying mechanisms of Vagus Nerve Stimulation (VNS) in the treatment of Chronic Congestive Heart Failure (CHF) remain insufficiently elucidated. Therefore, this study aims to investigate the therapeutic potential and mechanisms of VNS in treating CHF. In this study, models of CHF and VNS were established prior to performing echocardiography, H&E staining, and flow cytometry to evaluate the effects of VNS on pathological damage associated with CHF and myocardial mitochondrial dysfunction. Multi-omics analysis was conducted to identify changes in metabolites, gut microbiota, and gene expression following VNS treatment. Finally, QPCR was applied to measure levels of essential genes at the mRNA levels. VNS effectively enhances cardiac function, improves metabolic processes, and reduces inflammatory factor levels in dogs with CHF. VNS alleviates myocardial pathological damage, prevents the accumulation of ROS, and increases mitochondrial membrane potential. Multi-omics analysis identified five key metabolites, four key microorganisms, and sixty key genes. Furthermore, combined multi-omics analysis revealed key therapeutic targets, including three metabolites, four microorganisms, and sixteen genes. VNS significantly downregulates the mRNA expression levels of FSTL3, TNFRSF12A, and HBEGF. In summary, VNS has demonstrated effectiveness in the treatment of CHF. Key therapeutic targets identified include Kamahine C, FSTL3, TNFRSF12A, and HBEGF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.